Erythropoietin Mechanism and Response
Mechanism of Action
- When tissue oxygenation decreases due to anemia, specialized interstitial cells in the kidney cortex sense hypoxia and produce erythropoietin, which binds to receptors on erythroid colony-forming units (CFU-Es), salvaging them from programmed cell death (apoptosis) 1
- Erythropoietin increases the production of reticulocytes, which are immature red blood cells released from bone marrow 1
Timing of Reticulocyte Response
- Pharmacokinetic studies show that once weekly dosing intervals with higher doses of EPO achieve similar rises in reticulocyte counts compared with thrice-weekly intervals 2
Dosing Considerations
- The recommended starting dose for EPO in cancer patients is 150 U/kg three times weekly for a minimum of 4 weeks, and alternative weekly dosing regimen (40,000 U/week) can also be considered based on common clinical practice 2
Monitoring Response
- EPO therapy is often associated with macrocytosis due to shifting of immature (large) reticulocytes into circulation 3, 4
Factors Affecting Response
- Folate and vitamin B12 deficiency can impair optimal hemoglobin synthesis and response to EPO 3, 4
- Inflammation can impair both the early erythropoietin-dependent period of erythropoiesis and the later iron-dependent period 1
- Certain conditions like hemoglobinopathies (sickle cell disease, thalassemia) may respond poorly to EPO therapy 3, 4
Clinical Applications
- For patients not responding to EPO (no 1-2 g/dL rise in hemoglobin level after 6-8 weeks), therapy should be discontinued and underlying causes investigated 5